Effect of ghrelin on serum metabolites in Alzheimer’s disease model rats; a metabolomics studies based on 1H-NMR technique

Document Type: Original Article


1 Faculty of Paramedical Sciences, Department of Basic Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

3 Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran


Objective(s): Alzheimer’s disease (AD) is dysfunction of the central nervous system and as a neurodegenerative disease. The objective of this work is to investigate metabolic profiling in the serum of animal models of AD compared to healthy controls and then to peruse the role of ghrelin as a therapeutic approach for the AD.
Materials and Methods: Nuclear magnetic resonance (NMR) technique was used for identification of metabolites that are differentially expressed in the serum of a rat model of the AD with or without ghrelin treatment. Using multivariate statistical analysis, models were built and indicated.
Results: There were significant differences and high predictive power between AD and ghrelin-treated groups. The area under curve (AUC) of receiver operating characteristic (ROC) curve and Q2 were 0.870 and 0.759, respectively. A biomarker panel consisting of 14 metabolites was identified to discriminate the AD from the control group. Another panel of 12 serum metabolites was used to differentiate AD models from treated models.
Conclusion: Both panels had good agreements with clinical diagnosis. Analysis of the results displayed that ghrelin improved memory and cognitive abilities. Affected pathways by ghrelin included oxidative stress, and osteoporosis pathways and vascular risk factors.


Main Subjects

1. Ingram DK. Analysis of age‐related impairments in learning and memory in rodent models. Ann N Y Acad Sci 1985; 444:312-331.
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease report of the nincds‐adrda work group* under the auspices of department of health and human services task force on alzheimer’s disease. Neurology 1984; 34:939-939.
3. Eckert A, Hauptmann S, Scherping I, Rhein V, Müller-Spahn F, Götz J, et al. Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice. Neurodegenerative Dis 2008; 5:157-159.
4. Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003; 2:605-613.
5. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003; 30:1104-1113.
6. Kantarci K, Weigand SD, Petersen RC, Boeve BF, Knopman DS, Gunter J, et al. Longitudinal 1 H MRS changes in mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging 2007; 28:1330-1339.
7. Lindon JC, Nicholson JK, Holmes E. The handbook of metabonomics and metabolomics: Elsevier; 2011.
8. Nicholson G, Rantalainen M, Maher AD, Li JV, Malmodin D, Ahmadi KR, et al. Human metabolic profiles are stably controlled by genetic and environmental variation. Mol Syst Biol 2011; 7:525.
9. Lindon JC, Nicholson JK. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu Rev Anal Chem 2008; 1:45-69.
10. Fathi F, Ektefa F, Oskouie AA, Rostami K, Rezaei-Tavirani M, Alizadeh AHM, et al. NMR based metabonomics study on celiac disease in the blood serum.
Gastroenterol Hepatol Bed Bench 2013; 6:190.
11. Nobakht M. Gh BF, Arefi Oskouie A, Rezaei-Tavirani M, Aliannejad R, Taheri S, Fathi F, et al. NMR spectroscopy-based metabolomic study of serum in sulfur mustard exposed patients with lung disease. Biomarkers 2017; 22:413-419.
12. Doody RS. Current treatments for Alzheimer’s disease: cholinesterase inhibitors. J Clin Psychiatry 2003; 64:11-17.
13. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging 2008; 3:211.
14. Zemek F, Drtinova L, Nepovimova E, Sepsova V, Korabecny J, Klimes J, et al. Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf 2014; 13:759-774.
15. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001; 50:227-232.
16. Lawrence CB, Snape AC, Baudoin FM-H, Luckman SM. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology 2002; 143:155-162.
17. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350:2362-2374.
18. Tesauro M, Schinzari F, Iantorno M, Rizza S, Melina D, Lauro D, et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 2005; 112:2986-2992.
19. Granado M, Priego T, Martín AI, Villanua MA, López-Calderón A. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab. 2005; 288:E486-E492.
20. Gahete MD, Córdoba-Chacón J, Kineman RD, Luque RM, Castaño JP. Role of ghrelin system in neuroprotection and cognitive functions: implications in Alzheimer’s disease. Peptides 2011; 32:2225-2228.
21. Aleman A, Torres-Alemán I. Circulating insulin-like growth factor I and cognitive function: neuromodulation throughout the lifespan. Prog Neurobiol 2009; 89:256-265.
22. Goodsaid F, Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J. 2007; 9:E105-E108.
23. González-Domínguez R, Sayago A, Fernández-Recamales Á. Metabolomics in Alzheimer’s disease: The need of complementary analytical platforms for the identification of biomarkers to unravel the underlying pathology. J Chromatogr B Analyt Technol Biomed Life Sci. 2017; 1071:75-92.
24. Goshadrou F, Kermani M, Ronaghi A, Sajjadi S. The effect of ghrelin on MK-801 induced memory impairment in rats. Peptides 2013; 44:60-65.
25. Ghavipanjeh GR, Alaei H, Khazaei M, Pourshanazari AA, Hoveida R. Effect of acute and chronic hypertension on short-and long-term spatial and avoidance memory in male rats. Pathophysiology 2010; 17:39-44.
26. Tamburella A, Micale V, Mazzola C, Salomone S, Drago F. The selective norepinephrine reuptake inhibitor atomoxetine counteracts behavioral impairments in trimethyltin-intoxicated rats. Eur J Pharmacol 2012; 683:148-154.
27. Fathi F, Majari‐Kasmaee L, Mani‐Varnosfaderani A, Kyani A, Rostami‐Nejad M, Sohrabzadeh K, et al. 1H NMR based metabolic profiling in Crohn’s disease by random forest methodology. Magn Reson Chem 2014; 52:370-376.
28. Fathi F, Kasmaee LM, Sohrabzadeh K, Nejad MR, Tafazzoli M, Oskouie AA. The differential diagnosis of Crohn’s disease and celiac disease using nuclear magnetic resonance spectroscopy. Appl Magn Reson2014; 45:451-459.
29. Brown FF, Campbell ID, Kuchel PW, Rabenstein DC. Human erythrocyte metabolism studies by 1H spin echo NMR. FEBS Lett 1977; 82:12-16.
30. Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2007; 2:2692-2703.
31. Viant MR. Improved methods for the acquisition and interpretation of NMR metabolomic data. Biochem Biophys Res Commun 2003; 310:943-948.
32. Parsons HM, Ekman DR, Collette TW, Viant MR. Spectral relative standard deviation: a practical benchmark in metabolomics. Analyst 2009; 134:478-485.
33. Mahadevan S, Shah SL, Marrie TJ, Slupsky CM. Analysis of metabolomic data using support vector machines. Anal. Chem 2008; 80:7562-7570.
34. Cawley GC, Talbot NL. Efficient leave-one-out cross-validation of kernel fisher discriminant classifiers. Pattern Recognit 2003; 36:2585-2592.
35. Xia J, Psychogios, N., Young, N. and Wishart, D.S. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucl Acids Res 2009; 37:W652-660.
36. Xia J, Mandal, R., Sinelnikov, I., Broadhurst, D., and Wishart, D.S. MetaboAnalyst 2.0 - a comprehensive server for metabolomic data analysis. Nucl Acids Res 2012; 40:W127-133.
37. Xia J, Sinelnikov, I., Han, B., and Wishart, D.S. MetaboAnalyst 3.0 - making metabolomics more meaningful. Nucl Acids Res 2015; 43:W251-257.
38. Goshadrou F, Kermani M, Ronaghi A, Sajjadi S. The effect of ghrelin on MK-801 induced memory impairment in rats. Peptides 2013; 44:60-65.
39. Moon M, Choi JG, Nam DW, Hong H-S, Choi Y-J, Oh MS, et al. Ghrelin ameliorates cognitive dysfunction and neurodegeneration in intrahippocampal amyloid-β1-42 oligomer-injected mice. J Alzheimers Dis 2011; 23:147-159.
40. Barazzoni R, Bosutti A, Stebel M, Cattin MR, Roder E, Visintin L, et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2005; 288:E228-E235.
41. Andrews ZB, Erion D, Beiler R, Liu Z-W, Abizaid A, Zigman J, et al. Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. J Neurosci. 2009; 29:14057-14065.
42. Patil S, Chan C. Palmitic and stearic fatty acids induce Alzheimer-like hyperphosphorylation of tau in primary rat cortical neurons. Neurosci Lett 2005; 384:288-293.
43. Tan ZS, Seshadri S, Beiser A, Wilson PW, Kiel DP, Tocco M, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med 2003; 163:1053-1057.
44. Sims N, Finegan J, Blass JP, Bowen D, Neary D. Mitochondrial function in brain tissue in primary degenerative dementia. Brain Res 1987; 436:30-38.
45. Swerdlow RH. mitochondria and mitochondrial cascades in Alzheimer’s disease. J Alzheimers Dis 2017:1-14.
46. Ojaimi J, Byrne E. Mitochondrial function and Alzheimer’s disease. Neurosignals 2001; 10:254-262.
47. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer’s disease pathophysiology. Biochim Biophys Acta 2010; 1802:2-10.
48. Paglia G, Stocchero M, Cacciatore S, Lai S, Angel P, Alam MT, et al. Unbiased Metabolomic Investigation of Alzheimer’s Disease Brain Points to Dysregulation of Mitochondrial Aspartate Metabolism. J Proteome Res 2016; 15:608-618.
49. Rostamkhani F, Zardooz H, Goshadrou F, Baveisi M, Hedayati M. Stress increased ghrelin secretion from pancreatic isolated islets in male rats. Gen Physiol Biophys 2016; 35:109-117.
50. Gallant M, Rak M, Szeghalmi A, Del Bigio MR, Westaway D, Yang J, et al. Focally elevated creatine detected in amyloid precursor protein (APP) transgenic mice and Alzheimer disease brain tissue. J Biol Chem 2006; 281:5-8.
51. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp Gerontol 2000; 35:1363-1372.
52. Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta 1998; 1366:211-223.
53. Islam MT. Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. Neurol Res 2017; 39:73-82.
54. Müller WE, Eckert A, Kurz C, Eckert GP, Leuner K. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer’s disease—therapeutic aspects. Mol Neurosci 2010; 41:159-171.
55. Hoyer S, Nitsch R. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. J Neural Transm 1989; 75:227-232.
56. Clarke JR, Ribeiro FC, Frozza RL, De Felice FG, Lourenco MV. Metabolic dysfunction in Alzheimer’s disease: from basic neurobiology to clinical approaches. J Alzheimers Dis 2018:1-22.
57. Fisher G, Lorenzo N, Abe H, Fujita E, Frey W, Emory C, et al. Free D-and L-amino acids in ventricular cerebrospinal fluid from Alzheimer and normal subjects. Amino acids 1998; 15:263-269.
58. Corso G, Cristofano A, Sapere N, La Marca G, Angiolillo A, Vitale M, et al. Serum amino acid profiles in normal subjects and in patients with or at risk of Alzheimer dementia. Dement Geriatr Cogn Dis Extra 2017; 7:143-159.
59. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 2002; 346:476-483.
60. Ho PI, Collins SC, Dhitavat S, Ortiz D, Ashline D, Rogers E, et al. Homocysteine potentiates β‐amyloid neurotoxicity: role of oxidative stress. J Neurochem 2001; 78:249-253.
61. Li J, Wang C, Zhang JH, Cai J-M, Cao Y-P, Sun X-J. Hydrogen-rich saline improves memory function in a rat model of amyloid-beta-induced Alzheimer’s disease by reduction of oxidative stress. Brain Res 2010; 1328:152-161.
62. Li Y, Hai J, Li L, Chen X, Peng H, Cao M, et al. Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development. Endocrine 2013; 43:376-386.
63. Hipkiss AR. Could carnosine or related structures suppress Alzheimer’s disease? J Alzheimers Dis 2007; 11:229-240.
64. Boldyrev A, Fedorova T, Stepanova M, Dobrotvorskaya I, Kozlova E, Boldanova N, et al. Carnisone increases efficiency of DOPA therapy of Parkinson’s disease: a pilot study. Rejuvenation Res 2008; 11:821-827.
65. Balasubramaniam A, Joshi R, Su C, Friend LA, Sheriff S, Kagan RJ, et al. Ghrelin inhibits skeletal muscle protein breakdown in rats with thermal injury through normalizing elevated expression of E3 ubiquitin ligases MuRF1 and MAFbx. Am J Physiol Regul Integr Comp Physiol 2009; 296:R893-R901.
66. Adler-Abramovich L, Vaks L, Carny O, Trudler D, Magno A, Caflisch A, et al. Phenylalanine assembly into toxic fibrils suggests amyloid etiology in phenylketonuria. Nat Chem Biol 2012; 8:701.
67. Kol N, Adler-Abramovich L, Barlam D, Shneck RZ, Gazit E, Rousso I. Self-assembled peptide nanotubes are uniquely rigid bioinspired supramolecular structures. Nano Lett 2005; 5:1343-1346.
68. Gazit E. A possible role for π-stacking in the self-assembly of amyloid fibrils. FASEB J 2002; 16:77-83.